Crude oil: Riding the expectations curve

Commodities 5 minutes to read

Ole Hansen

Head of Commodity Strategy

Summary:  The recent vaccine news have resulted in a strong comeback for the energy sector. The potential for vaccines being rolled out in the new year will support a recovery in fuel demand and with that the profitability for oil producers. But while stocks of major oil companies have surged higher, crude oil futures have managed less than half of those gains. We take a closer look at why that is.


What is our trading focus?

OILUKJAN21 – Brent Crude Oil (January)
OILUSDEC20 – WTI Crude Oil (December)
XLE:arcx - Energy Select Sector SPDR Fund
XOP:arcx - SPDR S&P Oil & Gas Exploration and Production
XES:arcx - SPDR S&P Oil & Gas Equipment & Services

____________________________________________________________________________________________________

Nowhere has the recent vaccine news from Pfizer/BioNTech and Moderna had a bigger positive impact than on the energy sector. The potential for vaccines being rolled out in the new year, thereby driving a recovery in global fuel demand, was received very positively by the market. Adding to this the so called rotation out of momentum into more traditional value stocks - such as energy - the foundation for renewed investor interest has emerged.

The sudden and rapid demand collapse back in March and April saw the sector take a massive beating as the price of crude oil slumped in response to the destabilizing impact of rising supply (Saudi/Russia price war) and the historic collapse in fuel demand as the world grinded to a halt.  Fast forward to today and while the current supply and demand situation has improved, the short-term demand outlook remains challenged by renewed lockdowns and reduced mobility across the western world. 

These developments which also include a near 1 million barrels/day rise in Libyan crude oil production, have so far been off-set by a strong recovery in Asian demand, led by China, Japan and South Korea while OPEC+ have kept production capped. Once rolled out, the vaccine should ensure a recovery in oil demand back towards trend. But first inventory levels and spare capacity held by OPEC+ need to be reduced and this may take us towards the second half of 2021 before a meaningful oil price recovery can occur.

With this in mind we still see the prompt price of crude oil struggling to break much higher anytime soon. However, the pull from rallying back month contracts and speculative buying at the front could see it higher in the short-term. To illustrate the current back month outperformance, the January 2022 Brent contract has outperform January 2021, the current front month by almost 2 dollars since January 9.

Source: Saxo Group

While energy futures may struggle to break higher until fundamentals show an actual improvement, the forward looking stock market do not have the same problem. Since the first vaccine news from Pfizer/BioNTech hit the wires on November 9, major oil companies have rallied strongly. The MSCI World Energy index had until yesterday risen by 21% while the XLE ETF tracking major U.S. energy producers had risen by 26%. Even after these strong gains, both of these are still down by more than 30% in 2020. During this time Brent and WTI crude oil futures have rallied by less than half of the gains seen at company level. 

While we believe that the energy sector eventually will see a strong revival, patience with regards to the futures market may still be required. While a vaccine eventually will drive a normalization in demand, we should not forget that crude oil and commodities in general do not, like equities, have the luxury of being able to roll forward expectations as supply and demand need to balance every day.

Later today at 15:30 GMT, the Energy Information Administration will release its “Weekly Petroleum Status Report”. Some nervousness crept into an otherwise strong futures market yesterday after the American Petroleum Institute saw crude oil stocks at 4.2 million barrels, somewhat higher than 1.2 million that a Bloomberg survey pointed to. As per usual I will post the results on my Twitter @Ole_S_Hansen.

Disclaimer

The Saxo Bank Group entities each provide execution-only service and access to Analysis permitting a person to view and/or use content available on or via the website is not intended to and does not change or expand on this. Such access and use are at all times subject to (i) The Terms of Use; (ii) Full Disclaimer; (iii) The Risk Warning; (iv) the Rules of Engagement and (v) Notices applying to Saxo News & Research and/or its content in addition (where relevant) to the terms governing the use of hyperlinks on the website of a member of the Saxo Bank Group by which access to Saxo News & Research is gained. Such content is therefore provided as no more than information. In particular no advice is intended to be provided or to be relied on as provided nor endorsed by any Saxo Bank Group entity; nor is it to be construed as solicitation or an incentive provided to subscribe for or sell or purchase any financial instrument. All trading or investments you make must be pursuant to your own unprompted and informed self-directed decision. As such no Saxo Bank Group entity will have or be liable for any losses that you may sustain as a result of any investment decision made in reliance on information which is available on Saxo News & Research or as a result of the use of the Saxo News & Research. Orders given and trades effected are deemed intended to be given or effected for the account of the customer with the Saxo Bank Group entity operating in the jurisdiction in which the customer resides and/or with whom the customer opened and maintains his/her trading account. Saxo News & Research does not contain (and should not be construed as containing) financial, investment, tax or trading advice or advice of any sort offered, recommended or endorsed by Saxo Bank Group and should not be construed as a record of our trading prices, or as an offer, incentive or solicitation for the subscription, sale or purchase in any financial instrument. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, would be considered as a marketing communication under relevant laws.

Please read our disclaimers:
- Notification on Non-Independent Investment Research (https://www.home.saxo/legal/niird/notification)
- Full disclaimer (https://www.home.saxo/en-hk/legal/disclaimer/saxo-disclaimer)

Saxo Capital Markets HK is a company authorised and regulated by the Securities and Futures Commission of Hong Kong. Saxo Capital Markets HK Limited holds a Type 1 Regulated Activity (Dealing in securities); Type 2 Regulated Activity (Dealing in Futures Contract) and Type 3 Regulated Activity (Leveraged foreign exchange trading) licenses (CE No. AVD061). Registered address: 19th Floor, Shanghai Commercial Bank Tower, 12 Queen’s Road Central, Hong Kong

By clicking on certain links on this site, you are aware and agree to leave the website of Saxo Capital Markets, proceed on to the linked site managed by Saxo Group and where you will be subject to the terms of that linked site.

Apple, iPad and iPhone are trademarks of Apple Inc., registered in the US and other countries. AppStore is a service mark of Apple Inc.

Please note that the information on this site and any product and services we offer are not targeted at investors residing in the United States and Japan, and are not intended for distribution to, or use by any person in any country or jurisdiction where such distribution or use would be contrary to local law or regulation. Please click here to view our full disclaimer.